Purpose: To study the structural, visual and refractive outcomes of intravitreal injection of aflibercept monotherapy in patients with high-risk prethreshold type 1 retinopathy of prematurity (ROP). Design: Prospective nonrandomized interventional case series study. Patients and Methods: 1 mg/0.025 ml intravitreal aflibercept was administered for patients with high-risk prethreshold type 1 ROP. The primary outcomes studied were unfavorable structural outcome, unfavorable visual outcome and unfavorable refractive outcome. The secondary outcomes were absence of recurrence, ocular and systemic adverse events. Results: Twenty-six eyes were enrolled in the study; all had completed 1 year of follow-up. The mean birth weight was 991 ± 266 g (range: 875-1,105 g); the mean gestational age at birth was 26.33 ± 2.1 weeks (range: 24-30 weeks); 9 eyes were graded as ROP with stage 2+, zone I retinopathy, 14 eyes had stage 3+ disease in zone II and 3 eyes were diagnosed with stage 3 disease in zone I. Twenty-five eyes (96.2%) showed a favorable structural and 21 (80.1%) a favorable visual outcome, and the median refractive error after 1 year was 0.75 dpt (range: -9.5 to +4). Conclusions: Intravitreal injection of aflibercept monotherapy is an easy, safe and effective alternative modality of therapy for high-risk prethreshold type 1 ROP. A further multicenter study with a longer duration of follow-up is required. © 2014 S. Karger AG, Basel

Keywords:
Retinopathy of prematurity, Intravitreal injection, Aflibercept
1.
Palmer EA, Flynn JT, Hardy RJ, Phleps DL, Phillips CL, Schaffer DB, et al: Incidence and early course of retinopathy of prematurity. Ophthalmology 1991;11:1628-1640.
2.
Cryotherapy for Retinopathy of Prematurity Cooperative Group: Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 1988;106:471-479.
3.
Palmer EA, Hardy RJ, Dobson V, et al; Cryotherapy for Retinopathy of Prematurity Cooperative Group: 15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of Cryotherapy for Retinopathy of Prematurity. Arch Ophthalmol 2005;123:311-318.
4.
Laser ROP Study Group: Laser therapy for retinopathy of prematurity. Arch Ophthalmol 1994;112:154-156.
5.
Axer-Siegel R, Maharshak I, Snir M, Friling R, Ehrlich R, Sherf I, et al: Diode laser treatment of retinopathy of prematurity. Anatomical and refractive outcomes. Retina 2008;28:839-846.
6.
Early Treatment for Retinopathy of Prematurity Cooperative Group: Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity randomized trial. Arch Ophthalmol 2003;121:1684-1694.
7.
Kwinta P, Bik-Multanowski M, Mitkowska Z, Tomasik T, Pietrzyk JJ: The clinical role of vascular endothelial growth factor (VEGF) system in the pathogenesis of retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008;246:1467-1475.
8.
Kim J, Kim SJ, Chang YS, Park WS: Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity. Retina 2014;34:77-82.
9.
Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza W, Jendritza B, Jonas JB: Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol 2013;155:1119-1124.
10.
Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group: Efficacy of intravitreal bevacizumab for stage 3 retinopathy of prematurity. N Engl J Med 2011;364:603-615.
11.
Castellanos MA, Schwartz S, García-Aguirre G, Quiroz-Mercado H: Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol 2013;97:816-819.
12.
Orozco-Gómez LP, Hernández-Salazar L, Moguel-Ancheita S, Ramírez-Moreno MA, Morales-Cruz MV: Laser-ranibizumab treatment for retinopathy of prematurity in umbral-preumbral disease. Three years of experience. Cir Cir 2011;79:207-214, 225-232.
13.
Autrata R, Senková K, Holousová M, Krejcírová I, Dolezel Z, Borek I: Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II - four years results. Cesk Slov Oftalmol 2012;68:29-36.
14.
Autrata R, Krejcírová I, Senková K, Holoušová M, Doležel Z, Borek I: Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. Eur J Ophthalmol 2012;22:687-694.
15.
Papadopoulos N, Martin J, Ruan Q, et al: Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171-185.
16.
Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA: Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS Study. Am J Ophthalmol 2013;155:429-437.
17.
Holash J, Davis S, Papadopoulos N, et al: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-11398.
18.
Royal College of Pediatrics and Child Health and Royal College of Ophthalmologists: Retinopathy of prematurity guideline. May 2008. http://www.rcophth.ac.uk/core/.
19.
Royal College of Ophthalmologists: Guideline of intravitreal injection by Royal College of Ophthalmologists. February 2009. http://www.rcophth.ac.uk/core.
20.
Dobson V, Quinn GE, Biglan AW, et al: Acuity card assessment of visual function in the Cryotherapy for Retinopathy of Prematurity trial. Invest Ophthalmol Vis Sci 1990;31:1702-1708.
21.
Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, Lopez PF: Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 2012;32:434-457.
22.
Meyer CH, Krohne TU, Holz FG: Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina. 2011;31:1877-1884.
23.
Foroozan R, Connolly BP, Tasman WS: Outcomes after laser therapy for threshold retinopathy of prematurity. Ophthalmology 2001;108:1644-1646.
24.
The Early Treatment for Retinopathy of Prematurity Group; Good WV, Hardy RJ, Dobson V, et al: Final visual acuity results in the Early Treatment for Retinopathy of Prematurity Study. Arch Ophthalmol 2010;128:663-671.
25.
Sahni J, Subhedar NV, Clark D: Treated threshold stage 3 versus spontaneously regressed subthreshold stage 3 retinopathy of prematurity: a study of motility, refractive, and anatomical outcomes at 6 months and 36 months. Br J Ophthalmol 2005;89:154-159.
26.
Bourla DH, Gonzales CR, Valijan S, Yu F, Mango CW, Schwartz SD: Association of systemic risk factors with the progression of laser-treated retinopathy of prematurity to retinal detachment. Retina 2008;28(suppl 3):S58-S64.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.